Improving acceptability of products for secondary prophylaxis
Improving acceptability of products for secondary prophylaxis including penicillin reformulation
Investigators: Andrew Steer, Anna Ralph, Asha Bowen, Dianne Sika-Paotonu, Jim Ramsay, Jonathan Carapetis, John Joseph, Julie Marsh, Julie Vine, Katherine Gray, Kevin Batty, Laurens Manning, Robert Hand, Rosemary Wyber, Sam Salman, Veronica Dolman.
Aims and timelines:
1. PK studies: to assess pharmacokinetics (PK) of people receiving benzathine penicillin G (BPG) secondary prophylaxis aged 5-21; and to identify potential evidence of breakthrough infection. Two sites: metro (Perth) and remote (likely Darwin). Timeline: underway – mid 2018.
2. Intramuscular versus subcutaneous administration of BPG: to assess potential difference in PK between routes of administration in healthy adult volunteers. Timeline: mid 2017 – early 2018.
3. Global quality of BPG: analytic study assessing the potency and evidence of breakdown products in powdered BPG. Timeline: underway – late 2017.
4. Preference study: to assess the opinions of patients, caregivers, and families on the ideal characteristics of a new formulation of BPG. Timeline: 2018.
Any queries for further information about the END RHD CRE can be directed to: